Methods and compositions for treating and preventing malaria using an invasion ligand directed to a protease-resistant receptor

US9134311B2 · kind B2 · utility

Assignee

• THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH · AU

Inventors

• Alan Cowman · Melbourne, AU
• Lin Chen · Hangzhou City, CN
• Jacob Baum · Melbourne, AU

Key dates

• Filing date: Aug 27, 2009
• Grant date: Sep 15, 2015
• Expiry date: Jun 20, 2030

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to an immunogenic molecule comprising a contiguous amino acid sequence of an invasion ligand of a strain of Plasmodium falciparum, the invasion ligand capable of binding to an erythrocyte receptor, the receptor function being resistant to trypsin and neuraminidase and chymotrypsin, wherein when administered to a subject the molecule is capable of inducing an immune response to the strain. The invention further relates to compositions and methods for the treatment of diseases such as malaria.